Canada markets closed
  • S&P/TSX

    20,144.04
    -86.92 (-0.43%)
     
  • S&P 500

    4,221.86
    -1.84 (-0.04%)
     
  • DOW

    33,823.45
    -210.22 (-0.62%)
     
  • CAD/USD

    0.8100
    +0.0007 (+0.08%)
     
  • CRUDE OIL

    70.93
    -0.11 (-0.15%)
     
  • BTC-CAD

    46,973.04
    -613.75 (-1.29%)
     
  • CMC Crypto 200

    938.66
    -31.22 (-3.22%)
     
  • GOLD FUTURES

    1,776.20
    +1.40 (+0.08%)
     
  • RUSSELL 2000

    2,287.46
    -27.23 (-1.18%)
     
  • 10-Yr Bond

    1.5110
    -0.0580 (-3.70%)
     
  • NASDAQ futures

    14,192.25
    +26.75 (+0.19%)
     
  • VOLATILITY

    17.75
    -0.40 (-2.20%)
     
  • FTSE

    7,153.43
    -31.52 (-0.44%)
     
  • NIKKEI 225

    29,018.33
    -272.68 (-0.93%)
     
  • CAD/EUR

    0.6796
    +0.0002 (+0.03%)
     

SELLAS Life Sciences to Host Shareholder Update Call on June 3rd

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update.

Event:

Shareholder Update Call

Date:

Thursday, June 3, 2021

Time:

8:30 a.m. ET

Live Call:

1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)

Webcast:

https://www.sellaslifesciences.com/investors/events-and-presentations

For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at https://www.sellaslifesciences.com/investors/events-and-presentations after the conclusion of the call.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

For more information, please contact:

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting